Departamento de Biomedicina Molecular, CINVESTAV IPN, Av. IPN # 2508 Col. San Pedro Zacatenco, México D. F., Mexico.
Arch Virol. 2010 Jun;155(6):847-56. doi: 10.1007/s00705-010-0652-x.
A DENV-2 plasmid named pEIIEIII/NS1,containing sequences encoding portions of the envelope protein that are potentially involved in the induction of neutralizing antibodies and a portion of the NS1 sequence that is involved in protection, is reported in this work. The synthesized subunit protein was recognized by human sera from infected patients and had the predicted size. The immunogenicity of this construct was evaluated using a mouse model in a prime-boost vaccination approach. The priming was performed using the plasmid pEIIEIII/NS1, followed by a boost with recombinant full-length GST-E and GST-NS1 fusion proteins. The mice showed specific antibody responses to the E and NS1 proteins, as detected by ELISA, compared to the response of animals vaccinated with the parental plasmid. Interestingly, some animals had neutralizing antibodies. These results show that EII*, EIII and NS1* sequences could be considered for the design ofa recombinant subunit vaccine against dengue disease.
本研究报告了一种名为 pEIIEIII/NS1的 DENV-2 质粒,该质粒含有可能诱导中和抗体的包膜蛋白部分序列和参与保护的 NS1 序列部分。合成的亚单位蛋白被感染患者的人血清识别,且具有预测的大小。使用小鼠模型通过初免-加强免疫接种方法评估了该构建体的免疫原性。初免使用质粒 pEIIEIII/NS1进行,然后用重组全长 GST-E 和 GST-NS1 融合蛋白加强。与用亲本质粒接种的动物的反应相比,小鼠对 E 和 NS1 蛋白表现出特异性抗体反应,通过 ELISA 检测到。有趣的是,一些动物具有中和抗体。这些结果表明,EII*、EIII 和 NS1*序列可被考虑用于设计针对登革热疾病的重组亚单位疫苗。